The effects of long-term monotherapy with felodipine, a calcium antagonist, on blood pressure, glucose tolerance, and serum lipid profiles were prospectively investigated in 51 hypertensive patients: 13 with normal glucose tolerance and 38 with glucose intolerance. The levels of plasma glucose, serum lipids, and glycosylated hemoglobin A lc were determined before and during long-term (7.5±0.5 months; range, 6 to 9 months) therapy with felodipine. A 75-g oral glucose tolerance test was performed before and during long-term felodipine therapy. Significant decreases in both systolic and diastolic blood pressures in both patient groups were maintained during the therapy. Neither fasting nor post-glucose load venous plasma glucose levels were altered in either group of patients, and no patients with normal glucose tolerance developed diabetes mellitus during the study. Serum lipid levels did not change significantly in either group of patients except for significant decreases in high-density lipoprotein cholesterol and apolipoprotein A-I in the group with normal glucose tolerance tests, but those changes remained within the normal range. Furthermore, neither serum lipid nor apolipoprotein levels were altered, even in patients with hypercholesterolemia (total cholesterol levels, >5.69 mmol/L=220 mg/ dL). These results suggest that long-term therapy with felodipine may not alter glucose and lipid metabolism in hypertensive patients, and felodipine appears to be useful as an antihypertensive agent for hypertensive patients with either dyslipidemia or impaired glucose metabolism. (Hypertension.
C hronic therapy with diuretics or /3-blockers in hypertensive patients has been shown to be associated with reversible deterioration in glucose tolerance and in lipid metabolism.'- 3 These adverse effects have been of particular concern because deterioration in glucose and/or lipid metabolism may pose additional risk for cardiovascular diseases. Recently, Ferrannini and coworkers 4 reported that patients with essential hypertension may have an insulin-resistant state that contributes to the development of glucose intolerance, dyslipidemia, and cardiovascular disease. Several investigators 510 examining the effects of antihypertensive drugs on glucose and lipid metabolism and/or insulin resistance in essential hypertension have found that angiotensin-converting enzyme inhibitors and a r blockers may improve glucose and lipid metabolism. There are several reports that calcium antagonists may have neutral effects on glucose and lipid metabolism in humans. 1114 On the contrary, there are some reports that calcium antagonists may suppress insulin secretion from isolated pancreatic /3-cells. 15 Moreover, some calcium antagonists may cause glucose intolerance. 1617 Felodipine is a long-acting calcium an- Correspondence to Hiroshi Shionoiri, MD, PhD, Second Department of Internal Medicine, Yokohama City University School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama 236, Japan. tagonist, and it has been suggested that felodipine is a useful antihypertensive agent. 1819 The present study, which was conducted in several centers, is a prospective evaluation of long-term felodipine therapy on blood pressure, glucose, and lipid metabolism in hypertensive patients with and without glucose intolerance and with and without hypercholesterolemia.
Methods
The subjects included 51 outpatients (24 men and 27 women; Table 1 ) with essential hypertension. Secondary causes of hypertension were excluded by endocrinological and radiological examinations, including renoscintigraphy, adrenoscintigraphy, and computed tomography in some patients. Thirteen of the 51 patients had normal glucose tolerance tests (NGT group). The remaining 38, designated the IGT group, included 14 patients with a diagnosis of non-insulin-dependent diabetes mellitus, all of whom had abnormal glucose tolerance tests, and 24 with impaired glucose tolerance using the criteria of the World Health Organization. 20 Informed consent was obtained from all patients, and the study was approved by each hospital's ethics committee. All antihypertensive medications and drugs affecting lipid metabolism were discontinued throughout the study. Patients were seen every month in the outpatient clinic, and blood pressure (BP) was measured three times with the patient in a sitting position at each visit. The average BP of the last two visits before the initiation of felodipine was higher than either 160 mm Hg systolic or 95 mm Hg diastolic in all patients. Basal levels of plasma glucose, serum insulin, glycosylated hemoglobin A lc (HbA lc ), serum total cholesterol (TC), triglyceride, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and apolipoproteins were determined in the morning after a 12-to 16-hour overnight fast. After BP was measured, blood samples were drawn at 30, 60, 120, and 180 
25±17
Before HDL indicates high-density lipoprotein; LDL, low-density lipoproteln. Data are expressed as mean±SD. There were no significant differences in clinical variables between the patient groups with normal glucose tolerance tests (NOT) and Impaired glucose tolerance tests (IGT) except for fasting plasma glucose and hemoglobin A )c .
*P<.05 vs NGT group.
minutes after a 75-g oral glucose load for measurement of glucose and insulin. After completion of the baseline evaluation, oral administration of felodipine was begun with a dose of 2.5 mg BID. The dose of felodipine was titrated upward during the subsequent outpatient clinic visits until sitting BP was less than 150/90 mm Hg. Determinations of glucose tolerance and insulin response, fasting levels of serum lipids, and HbA lc were repeated 7.5 ±03 months (range, 6 to 9 months) after the initiation of felodipine treatment. Venous plasma glucose was measured with an autoanah/zer by the hexokinase method, and serum insulin was estimated by radioimmunoassay using commercially available kits. Serum TC, triglyceride, and HDL-C were measured by enzymatic colorimetric methods. Serum apolipoprotein A-I and B levels were determined by the single radical immunodiffusion method. The results are expressed as mean±SD. The statistical analysis was made using repeatedmeasures analysis of variance. Dunnett-type multiple-comparison test and Wilcoxon signed-rank test were used. The null hypothesis was rejected for P<.05.
Results
There were no significant differences in clinical variables between the NGT and IGT groups except for fasting plasma glucose and HbA lc levels ( Table 1) . The mean treatment period with felodipine was 7.5 ±0.5 months (range, 6 to 9 months). Three patients were withdrawn from the study because of palpitation, flushing, dizziness, diarrhea, headache, and light-headed feeling, which immediately disappeared after cessation of felodipine. In addition, three patients dropped out of the study because of their noncompliance or protocol violations. In the other 15 patients, palpitation, dizzi- in BP and pulse rate after initiation of felodipine therapy in the NGT group are shown in Fig 1A, and those for the IGT group are shown in Fig IB. Throughout long-term felodipine therapy, both systolic and diastolic BP decreased significantly and similarly in both groups without significant change in pulse rate. Fig 2 (A  and B) illustrates the changes in mean plasma levels of glucose and serum levels of insulin after glucose loading in each group, before and during long-term felodipine treatment. Plasma glucose and serum insulin responses to a glucose load did not deteriorate in either group during therapy. The insulinogenic index (AIRI/ABS) was calculated as the ratio of the difference between the fasting and 30-minute post-glucose-load serum insulin levels and venous plasma glucose levels. Long-term felodipine therapy did not alter the insulinogenic index in either patient group. The concentrations of HbA lc also did not show any significant change in either group during long-term therapy. The mean values of serum lipids and apolipoproteins are shown in Table 2 . No significant changes in those values were found in either group during long-term felodipine therapy, except for decreases in HDL-C and apolipoprotein A-I in the NGT group (Table 2A) . When the subjects were subdivided into two groups (Table 2B ) -one with serum TC levels of less than 5.69 mmol/L (220 mg/dL) and the other with levels of more than 5.69 mmol/L (hypercholesterolemia) -long-term therapy did not alter serum Iipid and apolipoprotein levels in either patient group with or without hypercholesterolemia. There were no remarkable changes in body mass index, peripheral blood cell counts, serum electrolytes, creatinine, or enzymes during the long-term therapy. Plots of changes in plasma glucose and serum Insulin (IRI) levels after a 75-g oral glucose load in patients with normal glucose tolerance (A) and wttti Impaired glucose tolerance (B) before and during long-term felodlpine therapy. AIRI/ABS Indicates the insulinogenlc index, which was calculated as the ratio of the difference between the fasting and 30-minute post-glucose toad serum insulin levels and venous plasma glucose (BS) levels. Long-term fetodiplne therapy did not alter glucose tolerance and insulin responses to a glucose toad In both patient groups. There also were no notable changes in the insulinogenic index and HbA 1c in either patient group during the long-term therapy.
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extended period. These metabolic effects of diuretics may reduce or abolish their ability to lower morbidity and mortality. 12 Several reports have suggested that /3-blockers also impair glucose metabolism in normal and diabetic hypertensive patients.
37 - 8 The Framingham cohort analysis 21 noted that an increase in plasma glucose from 70 to 79 mg/dL to 90 to 99 mg/dL was associated with an increase in the incidence of cardiovascular diseases of 11% in men and 21% in women. This finding indicates that minor increases in plasma glucose are associated with a higher incidence of cardiovascular mortality and morbidity even if fasting glucose levels remain within the normal range. In addition, the hyperglycemic effect of diuretics has been found to be augmented by concomitant use of /3-blockers. 22 A reduction in HDL-C as well as increases in serum triglyceride and TC levels are considered to be risk factors for the development of coronary artery diseases. ' 2324 It is known that a r blockers have a favorable effect on serum lipid profiles. 25 We and other investigators 5 -6 -810 have reported that long-term treatment with several angiotensin converting enzyme inhibitors may have beneficial effects on glucose and lipid metabolism through improving insulin sensitivity. Recently, calcium antagonists have been established as one of the first-line drugs as well as diuretics, /3-blockers, angiotensin-converting enzyme inhibitors, a,-blockers, and a^-blockers for the treatment of hypertension because of their promising depressor effect and relative tolerability 26 ; however, the metabolic effects on glucose are controversial during treatment with calcium antagonists.
1112 ' 16 Some investigators have reported that calcium antagonists may worsen glucose metabolism through suppression of pancreatic insulin secretion, and other investigators have pointed out that glucose metabolism improved slightly with calcium antagonists. There are also some reports that calcium antagonists may have neutral effects on glucose and lipid metabolism, 13 -14 although some studies indicate a decrease in TC and LDL-C levels. 17 In the present study, glucose tolerance was not affected by long-term therapy with felodipine, regardless of the glucose tolerance of the patients and their insulinogenic index. The values of HbAi c in both NGT and IGT groups did not alter from their baseline values, indicating that long-term therapy does not affect glucose metabolism. Serum lipid levels did not change significantly in either group of patients, except for significant decreases in HDL-C and apolipoprotein A-I in the NGT group, but those changes remained within the normal range. Furthermore, fasting serum levels of lipids and apolipoproteins did not change during chronic therapy in patients with or without hypercholesterolemia. Overall, our results suggest that treatment with felodipine may have a metabolic neutral effect on glucose and lipid metabolism in hypertensive patients with or without glucose intolerance or hypercholesterolemia. It is known that the effects of lifestyle modification 26 may not only decrease blood pressure but also improve glucose and lipid metabolism. As there was no control group treated with placebo in the present study, interference by factors other than felodipine per se cannot be entirely excluded, ie, these results regarding glucose and lipid metabolism may be explained in part as results of the better attention given to daily diet and exercise by the patients even though there were no significant changes in body mass index during long-term therapy with felodipine. Although some antihypertensive drugs unfavorably influence carbohydrate and lipid metabolism, felodipine has an advantage in that it can be used without worsening glucose and lipid metabolism regardless of whether the patient has glucose intolerance and/or hypercholesterolemia.
